Friday, February 19, 2010
GlaxoSmithKline/XenoPort get negative response from FDA
UK drugs giant GlaxoSmithKline and partner XenoPort have received a negative response from the US Food and Drug Administration regarding their marketing application for their restless legs syndrome (RLS) drug.
ORDER THE PAPERBACK
'THE EVIDENCE, HOWEVER, IS CLEAR...THE SEROXAT SCANDAL' By Bob Fiddaman
SIGNED COPIES HERE OR UNSIGNED FROM CHIPMUNKA PUBLISHING
About the Author :
Bob Fiddaman has been writing about the dangers of antidepressants since 2006. In 2011 he was presented with two human rights awards from the Citizens Commission on Human Rights.
Labels: BOB FIDDAMAN, Fiddaman, fiddaman blog, Paxil, Seroxat, Seroxat Sufferers Stand Up and be Counted, THE EVIDENCE HOWEVER IS CLEAR